MB-WXAT@EC2612A

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Acceleration of Chinese Innovative Drugs Internationalization and Wuxi Biologics' Exceeding Expectations in Q1 2026

BlackRock Increases Holding in Wuxi Biologics H Shares

HSBC Upgrades Wuxi Biologics Rating and Target Price

Goldman Sachs Analyst Gives Buy Rating to WuXi AppTec's H Shares

JPMorgan Raises Target Price for WuXi AppTec to HKD 172

Morgan Stanley Upgrades Rating on Wuxi Biologics Due to Strong Earnings

UBS Raises Goal Price and Earnings Forecast for Wuxi Biologics

WUXI APPTEC released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue HKD 14.1 B (forecast HKD 12.19 B), actual EPS HKD 1.7913 (forecast HKD 1.3856)

WuXi AppTec Reiterates Its 2026 Revenue Guidance

WuXi AppTec Plans to Expand Capacity to Meet Order Demand

WuXi AppTec Reports Strong Core Business Growth in Q1

Company Continues to Focus on and Strengthen CRDMO Business Model

CLSA Raises Revenue and Profit Forecasts for Wuxi Biologics, Maintains Overweight Rating

Citi Raises Target Price on Wuxi Biologics to HKD 158.5

WUXI APPTEC to release FY2026 Q1 earnings on April 27 After-Market BJT, forecast revenue HKD 12.24 B, EPS HKD 1.3914

WuXi AppTec Reports Record Operational Performance in 2025 Annual Report

China Renaissance Maintains Buy Rating on WuXi

JPMorgan Raises 2026-2028 Sales Forecast and Target Price for Wuxi Biologics

RADIANCE HLDGS

ANCHORSTONE

RIVERINE CHINA

REACH NEW HLDGS

FINELAND LIVING

NUR HOLDINGS

GOLDEN LEAF INT

UBOT HOLDING

MAN YUE TECH

603259

02359

UBS reported that WUXI APPTEC announced the issuance of RMB6.78 billion one-year zero-coupon convertible bonds at 103.5% of the principal amount. The initial conversion price is HKD153 per share, a 17.6% premium over the previous closing price. UBS views this as slightly positive, reflecting management's confidence, and has set a target price of HKD171.2 with a Buy rating.

AASTOCKS News

WuXi AppTec

WUXI APPTEC

UBS Group AG

UBS: WUXI APPTEC  Zero-Coupon Convertible Bond Issuance Slightly Positive, Reflects Management Confidence

159892

512010

520880

159837

516500

562050

Wuxi AppTec plans to raise approximately $1 billion through U.S. dollar-settled zero coupon convertible bonds to enhance its capacity and capabilities. The bonds, convertible to shares at an initial price of HK$153, represent about 9.1% of the enlarged H-share capital. The proceeds will be used for global expansion and corporate purposes. Morgan Stanley, Citigroup, and Goldman Sachs are advising on the issuance.

MorningStar

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund CSI 300 Health Care ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

Minsheng Royal CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Morgan Stanley

Citigroup

Goldman Sachs

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

GS Hldg R

Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds

520690

Dannuo Pharmaceuticalhas launched its IPO today, offering 8.2806 million H shares at HKD75.7 each, with an entry fee of HKD3,823.17 per lot. The public offering will close on May 19, and listing is expected on May 22. The company aims to raise approximately HKD558 million, primarily for R&D and commercialization of its products. WUXI APPTEC is a cornerstone investor, holding about 5.5% of the company post-offering. Dannuo focuses on bacterial infections and has a pipeline of seven innovative projects, including two core products for treating various infections.

Bosera Hang Seng SCHK Innovative Drug Select ETF

CITIC SEC

CITIC Securities Co., Ltd.

Orient Corporation

Dannuo Pharmaceutical  Starts IPO Today; Entry Fee HKD3,823.17 per Lot; WUXI APPTEC Participates in Early-stage Investment

02509

WXXWY

JPMorgan's report highlights the National Healthcare Security Administration's new plan for the 2026 National Reimbursement Drug List, which allows drugs to apply for NRDL inclusion before formal approval. This change is expected to enhance the commercialization prospects for innovative drug developers in China. The report identifies INNOVENT BIO, WUXI APPTEC, WUXI XDC, and SKB BIO as top picks, benefiting from clearer pricing rules and faster market access for high-priced drugs.

QYUNS-B

WuXi Biologics

SKB BIO

WUXI BIO

TEDA BIOMEDICAL

INNOVENT BIO

WUXI XDC

China Southern Hang Seng Biotech ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

Penghua SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

ICBCCS SSE STAR Biology and Medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

Tianhong CNI BIOMEDICINE ETF

China Merchants CSI Biotechnology Theme ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Yinhua CSI Innovative Drugs Industry ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Ping An CSI Medicine and Medical Device Innovation ETF

Penghua CSI HK Connect Health Care Composite ETF

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

Citi's research report highlights ongoing improvements in China's healthcare sector, driven by innovative drugs and CDMOs. Key segments have stabilized, with sales of innovative drugs accelerating and record CXO order volumes. Upcoming catalysts include data releases and licensing momentum. Citi updated its Hong Kong Buy list, featuring top picks WUXI APPTEC, WUXI BIO, and ALI HEALTH, while noting sector-specific challenges have been largely absorbed by the market.

Bosera Hang Seng Health Care ETF(QDII)

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Universal 800 Health Care ETF

ALI HEALTH

HENGRUI PHARMA

Hengrui Pharma

CSPC PHARMA

ASCLETIS-B

MircroPort Medbot-B

Mindray

Aier

Yifeng Pharmacy

CR MEDICAL

Bloomage Biotech

Citi: Fundamentals of China Healthcare Sector Continue to Improve; Top Picks WUXI APPTEC , WUXI BIO , ALI HEALTH

HSBC Research has raised the target price for WUXI APPTECto HKD162.5 while maintaining a Buy rating. The company reported a YoY revenue growth of 39.4% and a 71.7% increase in adjusted net profit for Q1. The small molecule CDMO business saw an 80.1% YoY surge, exceeding expectations. HSBC also increased its adjusted net profit forecasts for 2026-2028 by 5-6% and anticipates a CAGR of 14.8% in revenue and 17.3% in adjusted net profit from 2025 to 2028.

HSBC HOLDINGS

HSBC

HSBC 5xShortSG241213

HSBC Holdings Plc

HSBC Research Raises WUXI APPTEC  TP to HKD162.5, Maintains Buy

At today's close, WuXi AppTec's stock price fell sharply by 3.7% to HKD 137.8, after reaching a high of HKD 144.2 during the day and then weakening throughout, ultimately closing in the lowest range of the day. The total trading volume was approximately HKD 1.58 billion, significantly larger compared to recent levels. It is noteworthy that despite the deep single-day decline in stock price, bullish signals have begun to emerge at the daily MACD level, with the convergence of DIF and DEA often indicating that the previously sustained downward momentum is marginally weakening, and the short selling pressure may be entering a phase of release. Although today's high open and low close trend is relatively weak, from a trend cycle perspective, the emergence of this bullish signal is typically regarded as one of the early characteristics of a phase bottom. On the news front, the CXO sector has recently continued to attract market attention. The expectation that the Federal Reserve will remain steady at the April FOMC meeting has basically materialized, and Powell's strong statements have further cooled market expectations for interest rate cuts, putting short-term pressure on global risk appetite. For WuXi AppTec, the rhythm of overseas customer orders and exchange rate fluctuations are the core variables affecting performance. In addition, the Hong Kong stock pharmaceutical sector has recently undergone a round of adjustments, with peers like WuXi Biologics and CanSino Biologics also showing weak performance, creating additional pressure on WuXi AppTec due to the resonance effect of capital outflows in the sector. However, as a global leader in CRO/CDMO, the company's resilience during the industry's order recovery cycle is still viewed positively by some institutions

Technical Forecast

AKESO

Pre-market trend | WuXi AppTec (2359.HK) shows bullish signals amid a significant pullback on 4/29. Can it stabilize and rebound?

Goldman Sachs analyst Ziyi Chen has assigned a Buy rating to WuXi AppTec Co., Ltd. Class H (2359) with a price target of HK$169.40. The stock closed at HK$143.10. Chen, who focuses on the Healthcare sector, has an average return of 2.8% and a 45.68% success rate on recommendations. The analyst consensus for WuXi AppTec is Strong Buy, with a price target consensus of HK$157.63.

Tip Ranks

LIVZON PHARMA

LIVZON GROUP

3SBIO

Legend Biotech

Sunshine Guojian Pharmaceutical

WuXi AppTec Co., Ltd. Class H (2359) Receives a Buy from Goldman Sachs

G Sachs has raised its target price for WUXI APPTECto HKD169.4, maintaining a Buy rating. The company reported strong Q1 results, with a 25% increase in new orders and a 29% rise in backlog, driven by growth across all major business segments. Non-IFRS earnings forecasts for 2026-2028 were increased by 7% to 7.6%. Management plans to review guidance in Q2, while the small molecule CDMO business continues to show solid growth.

G Sachs Raises WUXI APPTEC  TP to HKD169.4, Business Growth Shows Resilience

MB-WXAT@EC2612A(29290.HK)

UBS: WUXI APPTEC Zero-Coupon Convertible Bond Issuance Slightly Positive, Reflects Management Confidence

Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds

Dannuo Pharmaceutical Starts IPO Today; Entry Fee HKD3,823.17 per Lot; WUXI APPTEC Participates in Early-stage Investment

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

Citi: Fundamentals of China Healthcare Sector Continue to Improve; Top Picks WUXI APPTEC , WUXI BIO , ALI HEALTH

HSBC Research Raises WUXI APPTEC TP to HKD162.5, Maintains Buy

Pre-market trend | WuXi AppTec (2359.HK) shows bullish signals amid a significant pullback on 4/29. Can it stabilize and rebound?

WuXi AppTec Co., Ltd. Class H (2359) Receives a Buy from Goldman Sachs

G Sachs Raises WUXI APPTEC TP to HKD169.4, Business Growth Shows Resilience